The DEAL-HF trial performed serial echocardiographic measures in 240 HF patients with NYHA Class-III and -IV symptoms and found a positive association between increased plasma concentrations of Gal-3 and changes in LVEDV, whilst there was no correlation between baseline LVEDV and Gal-3 levels (39). This evidence concerns the gene LGALS3 and hydrops fetalis.